Medicom expands into branding
May 19, 2006Business Services
PR and medical education group Medicom has launched a new consultancy that offers product and corporate branding services.The new division, …
Industry experts to advise Northwick Park investigation
May 19, 2006Research and Development
Experts from the UK's pharmaceutical and biotech industries are to assist the inquiry into the Northwick Park drug trial, which …
AstraZeneca’s
May 18, 2006Research and Development, Sales and Marketing
AstraZeneca is to buy Cambridge Antibody Technology for 702 million pounds in a bid to expand its reach into biotechnology.Cambridge …
Seroxat raises suicide risk in young adults, says GSK
May 17, 2006Sales and Marketing
GlaxoSmithKline says new analyses of its antidepressant Seroxat show the drug raises the risk of suicidal behaviour in young adults.The …
Blair speaks out against animal extremists
May 15, 2006Sales and Marketing
Prime Minister Tony Blair has spoken out against animal rights activists, saying it was time for the 'silent majority' to …
UK government declares ‘end to Prozac nation’
May 12, 2006Sales and Marketing
People suffering from depression in the UK have been promised easier access to counselling and 'talking therapies' by the government, …
Pfizer’s smoking cessation drug approved
May 12, 2006Sales and Marketing
Chantix, a new drug which could help smoker's kick their habit and boost Pfizer's sales by billions has been approved …
Kendle spends $215 million to become major clinical research player
May 12, 2006Research and Development
Kendle is to spend $215 million on buying the business of rivals Charles River, a move which the companys leaders …
Merck buys antibody design specialists
May 10, 2006Research and Development
Merck is to buy a pioneering biotech company, which discovers new monoclonal antibodies and then re-engineers them to make them …
Scotland clears Femara for early breast cancer
May 9, 2006Sales and Marketing
Femara has been recommended for use in Scotland to prevent breast cancer returning after surgery, prompting its manufacturers and stakeholders …
Janssen-Cilag submits new schizophrenia drug
May 8, 2006Sales and Marketing
A new slow-release drug for schizophrenia has been filed for approval in Europe by Jannsen-Cilag, the manufacturers of top-selling Risperdal.Paliperidone …
Sanofi profits jump in first quarter
May 5, 2006Sales and Marketing
Sanofi-Aventis has recorded a major increase in its profits in the first three months of 2006, boosted by product growth …
AstraZeneca abandons diabetes drug over safety concerns
May 5, 2006Research and Development AstraZeneca, PPAR agonist
AstraZeneca is to abandon its late-stage diabetes drug Galida after new results raised doubts about its safety.Galida is a PPAR …
Frontline NHS staff enlisted in fight against flab
May 5, 2006The nation's increasing weight is to become top priority for frontline NHS staff in an effort to halt the rise …
AstraZeneca to co-market nanotechnology cancer drug
May 4, 2006Sales and Marketing
Groundbreaking nanotechnology is behind a new drug, which AstraZeneca and co-marketers Abraxis BioScience believe could be a major advance in …
Project management: from apprentice to master
May 3, 2006Research and Development, Sales and Marketing
When the three 'Apprentices' enter Mr. Sugars boardroom to explain why they made such a hash of their latest project, …
Is pharma fit for the future?
May 3, 2006Sales and Marketing
It's getting personal. While the pharma industry continues to debate the end of the blockbuster model, hardly a single clinician, …
Positive results halt trial of new Herceptin rival
May 3, 2006Research and Development
Better than expected results for a new drug for advanced breast cancer have led to trials being halted, in order …
Herceptin and the rise of patient power
May 3, 2006Sales and Marketing
The controversy surrounding Herceptin and its use in patients with early stage breast cancer has become a graphic illustration of …
Brands:looking at the bigger picture
May 3, 2006Sales and Marketing
While the prospect of a single-product company might seem attractive – no in-fighting over resource allocation, no conflicts of interest, …
Latest content
FibroFind appoints Lee Borthwick as CEO
